Mereo BioPharma Group plc Sponsored ADR Stock

$4.25

0.70% day before yesterday

Nasdaq, Sep 20, 10:10 pm CET

ISIN

US5894921072

Symbol

MREO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Mereo BioPharma Group plc Sponsored ADR Stock price

$4.25

+1.05 32.81% 5Y

Nasdaq, Closing price Fri, Sep 20 2024

-0.03 0.70%

ISIN

US5894921072

Symbol

MREO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$653.50m
Enterprise Value	$572.23m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	65.10
P/S ratio (TTM) P/S ratio	74.35
P/B ratio (TTM) P/B ratio	8.31
Revenue (TTM) Revenue	$8.79m
EBIT (operating result TTM) EBIT	$-41.30m
Free Cash Flow (TTM) Free Cash Flow	$-37.34m
Cash position	$87.43m
EPS (TTM) EPS	$-0.25
P/E forward	negative
P/S forward	27.04
EV/Sales forward	23.68
Short interest	3.47%

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Get Started for Free Today

Mereo BioPharma Group plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

5 Analysts have issued a Mereo BioPharma Group plc Sponsored ADR forecast:

5x Buy

100%

More details on Analyst Estimates Including Price Targets

5 Analysts have issued a Mereo BioPharma Group plc Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Mereo BioPharma Group plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '23		+/- %
Revenue	8.79 8.79	- 100%
- Direct Costs	3.20 3.20	425% 425% 36%
Gross Profit	5.59 5.59	1,016% 1,016% 64%
- Selling and Administrative Expenses	23 23	18% 18% 257%
- Research and Development Expense	23 23	35% 35% 266%
EBITDA	-40 -40	27% 27% -460%
- Depreciation and Amortization	0.86 0.86	19% 19% 10%
EBIT (Operating Income) EBIT	-41 -41	27% 27% -470%
Net Profit	-31 -31	30% 30% -356%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Mereo BioPharma Group plc Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

9 days ago

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:55am ET / 03:55pm BST.

Neutral

GlobeNewsWire

●

about one month ago

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates Cash of $87.4 million as of June 30, 2024 expected to fund operations into 2027 LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Co...

Neutral

GlobeNewsWire

●

3 months ago

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”). Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced...

More Mereo BioPharma Group plc Sponsored ADR News

Company Profile

Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Denise Scots-Knight
Employees	33
Founded	2015
Website	www.mereobiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now